FSLR
57
8
ZTS
36
7
LNC
45
-8
DTE
45
-2
GPC
22
-3
ITW
61
2
ES
53
-2
EMN
52
-4
WMB
63
-3
TMO
51
4
PBI
32
-3
AXP
63
3
BA
53
5
NOV
49
-3
FLS
67
4
UNH
55
2
WAT
55
24
ETR
66
-9
SE
52
2
TDC
75
12
FSLR
57
8
ZTS
36
7
LNC
45
-8
DTE
45
-2
GPC
22
-3
ITW
61
2
ES
53
-2
EMN
52
-4
WMB
63
-3
TMO
51
4
PBI
32
-3
AXP
63
3
BA
53
5
NOV
49
-3
FLS
67
4
UNH
55
2
WAT
55
24
ETR
66
-9
SE
52
2
TDC
75
12
Financhill
Back

Reshape Lifesciences 10K Form

Sell
28

RSLS
Reshape Lifesciences

Last Price:
5.80
Seasonality Move:
24.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RSLS News And Ratings

See the #1 stock for the next 7 days that we like better than RSLS

RSLS Financial Statistics

Sales & Book Value

Annual Sales: $8.68M
Cash Flow: $-1.36M
Price / Cash Flow: 0
Annual Sales: $5.99
Price / Book: 0.97

Profitability

EPS (TTM): -72.05850
Net Income (TTM): $-9.02M
Gross Margin: $5.55M
Return on Equity: -187.5%
Return on Assets: -100.3%

Reshape Lifesciences Earnings Forecast

Key Reshape Lifesciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for RSLS is 63.93%.
  • The Selling, General & Administrative Expenses for RSLS have been equal to 205.95% of Gross Profit Margin.
  • The Research & Development expenses have been 26.68% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of RSLS is -131.22% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

Reshape Lifesciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: RSLS
CUSIP: 761123
Website: reshapelifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.9
Quick Ratio: 0.77

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RSLS Technical Analysis vs Fundamental Analysis

Sell
28
Reshape Lifesciences (RSLS) is a Sell

Is Reshape Lifesciences a Buy or a Sell?